
Sign up to save your podcasts
Or


In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!
By Bernard Marini, Anthony Perissinotti, et al.4.5
2828 ratings
In the second portion of our two part-series on AML maintenance, Anthony and Bernie delve into the studies of post-transplant FLT3 inhibitor maintenance. We discuss the controversial MORPHO study of gilteritinib and whether these results will change practice!

498 Listeners

28 Listeners

184 Listeners

8,187 Listeners

2 Listeners

756 Listeners

12 Listeners

53 Listeners

57 Listeners

136 Listeners

1 Listeners

49 Listeners

185 Listeners

43 Listeners

3 Listeners